Who Paid My Doc
Vizamyl
Drug Core Imaging
NDC 17156-067-30
General payments
$51,967
Research payments
$294,731
Through program year 2022, $51,967 in general payments and $294,731 in research payments were reported against Vizamyl (Core Imaging).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $294,731 | 7 |
| 2021 | General | $36,805 | 19 |
| 2020 | General | $15,162 | 12 |
Breakdown
The top 5 of 11 recipients; each share is of general payments naming this product in 2021.
Each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.
The top 5 of 9 states; each share is of general payments naming this product in 2021 where a state was reported.
Records
31 general · 7 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.